A compound that could inhibit multiple targets associated with SARS-CoV-2 infection would prove to be a drug of choice against the virus. Human receptor-ACE2, receptor binding domain (RBD) of SARS-CoV-2 S-protein, Papain-like protein of SARS-CoV-2 (PLpro), reverse transcriptase of SARS-CoV-2 (RdRp) were chosen for in silico study. A set of previously synthesized compounds ( ) were docked into the active sites of the targets. Based on the docking score, ligand efficiency, binding free energy, and dissociation constants for a definite conformational position of the ligand, inhibitory potentials of the compounds were measured. The stability of the protein-ligand (P-L) complex was validated by using molecular dynamics simulations using the YASARA suit. Moreover, the pharmacokinetic properties, FMO and NBO analysis were performed for ranking the potentiality of the compounds as drug. The geometry optimizations and electronic structures were investigated using DFT. As per the study, compound- has the best binding affinity against all four targets. Moreover, compounds 1, 3 and 5 are less toxic and can be considered for oral consumption. [Abstract copyright: © 2022 Published by Elsevier B.V. on behalf of King Saud University.]

Cite as

Mohapatra, R., Azam, M., Mohapatra, P., Sarangi, A., Abdalla, M., Perekhoda, L., Yadav, O., Al-Resayes, S., Jong-Doo, K., Dhama, K., Ansari, A., Seidel, V., Verma, S. & Raval, M. 2022, 'Computational studies on potential new anti-Covid-19 agents with a multi-target mode of action', Journal of King Saud University - Science, 34(5), article no: 102086. https://doi.org/10.1016/j.jksus.2022.102086

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 16 June 2022
Was this page helpful?